Journal
SCIENCE
Volume 369, Issue 6499, Pages 77-+Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abc1932
Keywords
-
Categories
Funding
- National Key Research and Development Program [2020YFC0842100, 2020YFA0707500]
- CAMS initiative for Innovative Medicine of China [2016-I2M-2-006]
- National Key Research and Development Project of China [2016YFD0500304]
- Zhejiang Province Science and Technology Major Project [2020C03124]
- Beijing science and technology plan [Z201100005420006]
- Ten Thousand Talent Program
- NSFS Innovative Research Group [81921005]
- Strategic Priority Research Program [XDB29010000]
- National Mega projects of China for Major Infectious Diseases [2017ZX10304402]
Ask authors/readers for more resources
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available